利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

580 条记录 (耗时 0.042 秒)

    IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS
    4.
    发明申请
    IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS 审中-公开
    改进免疫球蛋白可变域

    公开(公告)号：WO2015173325A8

    公开(公告)日：2016-12-29

    申请号：PCT/EP2015060643

    申请日：2015-05-13

    申请人： ABLYNX NV

    发明人： BUYSE MARIE-ANGE ,  BOUTTON CARLO

    IPC分类号： C07K16/00 ,  C07K16/18 ,  C07K16/28

    CPC分类号： C07K16/00 ,  C07K16/18 ,  C07K16/2866 ,  C07K16/2875 ,  C07K2317/31 ,  C07K2317/567 ,  C07K2317/569

    摘要： VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

    摘要翻译： VH结构域，其中：（i）位置112处的氨基酸残基是K或Q中的一个; 和/或（ii）第89位的氨基酸残基是T; 和/或（iii）第89位的氨基酸残基是L并且第110位的氨基酸残基是K或Q之一; （iv）在（i）至（hi）的每种情况下，11位的氨基酸优选为V; 并且其中所述VH结构域含有C端延伸（X）n，其中n为1至10，优选1至5，例如1,2,3,4或5（并且优选1或2，例如 1）; （A），甘氨酸（G），缬氨酸（V），亮氨酸（L）或异亮氨酸（I）的氨基酸残基（优选天然存在的），并且优选独立选自丙氨酸 ）。

    ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF
    7.
    发明申请
    ASSAYS FOR DETECTING T CELL IMMUNE SUBSETS AND METHODS OF USE THEREOF 审中-公开
    用于检测细胞免疫接种的方法及其使用方法

    公开(公告)号：WO2016073378A1

    公开(公告)日：2016-05-12

    申请号：PCT/US2015/058674

    申请日：2015-11-02

    申请人： GENENTECH, INC. ,  F. HOFFMANN-LA ROCHE AG

    发明人： CHU, Felix ,  FOREMAN, Oded ,  ZIAI, James

    IPC分类号： G01N33/569 ,  G01N33/574

    CPC分类号： G01N33/56972 ,  A61K38/177 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2317/75 ,  C12Q1/06 ,  G01N33/57419 ,  G01N33/582 ,  G01N2333/70514 ,  G01N2800/52 ,  G01N2800/7028

    摘要： The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.

    摘要翻译： 本公开提供了通过标记在样品中显示CD4表达的淋巴细胞，然后标记在样品中表现出OX40表达的淋巴细胞，测量含有从受试者获得的癌细胞和淋巴细胞的样品中CD4 + OX40 + Foxp3 +淋巴细胞数目的方法， 在样品中显示Foxp3表达的淋巴细胞，然后测量样品中CD4 + OX40 + Foxp3 +淋巴细胞的数量。 还提供了用于确定受试者的预后的方法，预测具有癌症的受试者对OX40激动剂治疗的反应性，以及基于样品中CD4 + OX40 + Foxp3 +淋巴细胞数量来治疗或延缓癌症进展的方法。

    IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS
    9.
    发明申请
    IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS 审中-公开
    改进的免疫球蛋白可变域

    公开(公告)号：WO2015173325A3

    公开(公告)日：2016-02-18

    申请号：PCT/EP2015060643

    申请日：2015-05-13

    申请人： ABLYNX NV

    发明人： BUYSE MARIE-ANGE ,  BOUTTON CARLO

    IPC分类号： C07K16/00 ,  C07K16/18 ,  C07K16/28

    CPC分类号： C07K16/00 ,  C07K16/18 ,  C07K16/2866 ,  C07K16/2875 ,  C07K2317/31 ,  C07K2317/567 ,  C07K2317/569

    摘要： VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

    摘要翻译： VH结构域，其中：（i）第12位的氨基酸残基是K或Q之一; 和/或（ii）第89位的氨基酸残基为T; 和/或（iii）第89位的氨基酸残基为L，第10位的氨基酸残基为K或Q之一; 和（iv）在（i）至（hi）的每种情况下，第11位的氨基酸优选为V; 并且其中所述VH结构域含有C末端延伸（X）n，其中n为1至10，优选1至5，如1,2,3,4或5（优选1或2，如 1）; 并且每个X是独立选择的（优选天然存在的）氨基酸残基，优选独立地选自丙氨酸（A），甘氨酸（G），缬氨酸（V），亮氨酸（L）或异亮氨酸（I ）。

    TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA
    10.
    发明申请
    TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA 审中-公开
    多发性硬化症和神经病变的治疗

    公开(公告)号：WO2016003876A1

    公开(公告)日：2016-01-07

    申请号：PCT/US2015/038267

    申请日：2015-06-29

    申请人： OKLAHOMA MEDICAL RESEARCH FOUNDATION

    发明人： AXTELL, Robert, C.

    IPC分类号： C40B30/04

    CPC分类号： C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2875 ,  C07K2317/76 ,  G01N33/6893 ,  G01N2800/28 ,  G01N2800/285 ,  G01N2800/52

    摘要： The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject. Thus, in accordance with the present disclosure, there is provided a method for treating a subject having neuromyelitis optica (NMO) comprising administering to said subject an inhibitor of B-cell activating factor (BAFF) and/or an inhibitor or proliferating inducing ligand (APRIL).

    摘要翻译： 本公开提供了对象中的神经性脊髓炎（NMO）的诊断和预测。 它还提供了治疗受试者中的多发性硬化（MS）。 因此，根据本公开内容，提供了治疗患有神经性脊髓炎（NMO）的受试者的方法，包括向所述受试者施用B细胞活化因子（BAFF）抑制剂和/或抑制剂或增殖诱导配体 四月）。